J. GEOFFREY WALKER, M.B.
Clinical and animal trials with the new diuretic ethacrynic acid (2,3-dichloro-4(2 methylene butyryl) phenoxyacetic acid) suggest that it is exceptionally potent and in some cases far superior to either the organomercurials or the benzothiadiazines (1-13). A unique mode of action on the renal tubule has been suggested (10, 14-16). Because of the drug's potency, excessive loss of water and electrolytes with the development of hypochloremic alkalosis may occur (4, 5, 7, 8, 10, 12, 13). The only true side effects so far described, however, have been occasional gastrointestinal upsets (8, 10, 11) and hyperuricemia (7, 10), and no instance of
WALKER JG. Fatal Agranulocytosis Complicating Treatment with Ethacrynic Acid: Report of a Case. Ann Intern Med. ;64:1303–1305. doi: 10.7326/0003-4819-64-6-1303
Download citation file:
Published: Ann Intern Med. 1966;64(6):1303-1305.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use